ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • Doppler ultrasound
  • Doppler ultrasound and large vessel vasculitis
  • Doppler ultrasound and psoriatic arthritis
  • Doppler ultrasound and Risk Prediction
  • Doppler ultrasound and salivary gland
  • Doppler ultrasound and Shared Epitope
  • Doppler ultrasound and Synovial Immune Biology
  • dorsal root ganglia
  • doube negative T cell
  • Doxycycline
  • doxycycline and inflammation
  • DQB1*0601
  • drug
  • drug induced vasculitis and small vessel vasculitis
  • drug interactions
  • drug interactions and drug therapy
  • drug interactions and fibromyalgia
  • drug interactions and pain management
  • drug interactions and rheumatoid arthritis (RA)
  • Drug interactions and spondylarthropathy
  • drug repurposing
  • drug safety
  • drug safety and clinical trials
  • drug safety and drug persistence
  • Drug safety and health care cost
  • drug safety and health literacy
  • drug safety and infection
  • drug safety and registries
  • drug safety and rheumatoid arthritis
  • drug safety and rheumatoid arthritis (RA)
  • drug safety and safety
  • drug safety and tumor necrosis factor (TNF)
  • drug safety monitoring
  • drug safety monitoring and pregnancy
  • drug safety monitoring and quality measures
  • drug safety monitoring and randomized trials
  • drug safety monitoring and repository corticotropin injection
  • drug survival
  • drug therapy
  • drug therapy and clinical trials
  • drug therapy and drug safety
  • drug therapy and drug treatment
  • drug therapy and fibromyalgia
  • drug therapy and fracture risk
  • drug therapy and gout
  • drug therapy and iron metabolism
  • drug therapy and methotrexate (MTX)
  • drug therapy and osteoporosis
  • drug therapy and pharmacotherapy
  • drug therapy and proteinuria
  • drug therapy and psoriatic arthritis
  • drug therapy and rheumatoid arthritis (RA)
  • Drug therapy and systemic sclerosis
  • drug therapy and transcriptional regulation
  • drug therapy and treatment options
  • Drug toxicity
  • drug toxicity and hydroxychloroquine
  • drug toxicity and inflammatory arthritis
  • Drug toxicity and methotrexate (MTX)
  • drug toxicity and rheumatoid arthritis (RA)
  • drug toxicity and vasculitis
  • drug treatment
  • drug treatment and biologic drugs
  • drug treatment and clinical trials
  • drug treatment and imaging techniques
  • drug treatment and inflammation
  • drug treatment and medication
  • drug treatment and mouse model
  • drug treatment and osteoarthritis
  • drug treatment and outcomes
  • drug treatment and pharmacokinetics
  • drug treatment and rheumatic disease
  • drug treatment and rheumatoid arthritis (RA)
  • drug treatment and safety
  • drug treatment and steroid sparing
  • Drug-Drug Interference
  • Drug-Sparing Effect
  • dry eyes
  • dry eyes and genomics
  • dry eyes and measure
  • dry eyes and Rheumatoid Factor
  • DsDNA antibody
  • Dual energy x-ray absorptiometry (DEXA)
  • dual energy x-ray absorptiometry (DEXA) and bone health
  • dual energy x-ray absorptiometry (DEXA) and diagnosis
  • dual energy x-ray absorptiometry (DEXA) and Femur Fractures
  • dual energy x-ray absorptiometry (DEXA) and juvenile SLE
  • dual energy x-ray absorptiometry (DEXA) and osteoarthritis
  • Dual energy x-ray absorptiometry (DEXA) and osteoporosis
  • dual energy x-ray absorptiometry (DEXA) and parathyroid hormone
  • dual energy x-ray absorptiometry (DEXA) and positron emission tomography (PET)
  • dual energy x-ray absorptiometry (DEXA) and psoriatic arthritis
  • dual energy x-ray absorptiometry (DEXA) and rheumatoid arthritis (RA)
  • dual energy x-ray absorptiometry (DEXA) and spondylarthritis
  • dual energy x-ray absorptiometry (DEXA) and systemic lupus erythematosus (SLE)
  • dual energy x-ray absorptiometry (DEXA) and treatment
  • dual energy x-ray absorptiometry (DEXA) and ultrasound
  • dual femur
  • Dual-energy computed tomography
  • dual-energy CT and ultrasound
  • Duloxetine
  • DXA
  • DXA and osteoporosis
  • Dysmotility
  • Dyspnea
  • Dyspnea and systemic sclerosis
  • e health
  • E-Genes and Ancestry
  • Ear, Nose and Throat Involvement
  • early diagnosis
  • early retirement and socioeconomic factors
  • Early Rheumatoid Arthritis
  • Early Rheumatoid Arthritis and abatacept
  • Early Rheumatoid Arthritis and anti-CCP antibodies
  • Early Rheumatoid Arthritis and anti-citrullinated protein/peptide antibodies (ACPA)
  • Early Rheumatoid Arthritis and arthroscopy
  • Early Rheumatoid Arthritis and B cells
  • Early Rheumatoid Arthritis and biomarkers
  • Early Rheumatoid Arthritis and cardiovascular disease
  • Early Rheumatoid Arthritis and cartilage
  • Early Rheumatoid Arthritis and classification criteria
  • Early Rheumatoid Arthritis and comorbidity
  • Early Rheumatoid Arthritis and depression
  • Early Rheumatoid Arthritis and diabetes
  • Early Rheumatoid Arthritis and diagnosis
  • Early Rheumatoid Arthritis and fracture risk
  • Early Rheumatoid Arthritis and galectin
  • Early Rheumatoid Arthritis and Gene Expression
  • Early Rheumatoid Arthritis and glucocorticoids
  • Early Rheumatoid Arthritis and inflammation
  • Early Rheumatoid Arthritis and interferons
  • Early Rheumatoid Arthritis and lung
  • Early Rheumatoid Arthritis and Lung Disease
  • Early Rheumatoid Arthritis and methotrexate (MTX)
  • Early Rheumatoid Arthritis and outcome measures
  • Early Rheumatoid Arthritis and patient outcomes
  • Early Rheumatoid Arthritis and polyunsaturated fatty acid
  • Early Rheumatoid Arthritis and prediction model
  • Early Rheumatoid Arthritis and quality of life
  • Early Rheumatoid Arthritis and Rapid Radiograhic Progression
  • Early Rheumatoid Arthritis and remission
  • Early Rheumatoid Arthritis and rheumatoid arthritis (RA)
  • Early Rheumatoid Arthritis and tendonitis/bursitis
  • Early Rheumatoid Arthritis and tocilizumab
  • Early Rheumatoid Arthritis and treatment
  • Early Rheumatoid Arthritis and Triage
  • Early Rheumatoid Arthritis and ultrasonography
  • Early Rheumatoid Arthritis and Work Disability
  • Early treatment and remission induction
  • Ebola virus
  • EBV
  • ECLIPSE
  • Economics
  • economics and education
  • economics and etanercept
  • Economics and gout
  • economics and healthcare policy
  • economics and inflammatory arthritis
  • Economics and juvenile arthritis
  • economics and non-radiographic
  • economics and patient preferences
  • Economics and psoriatic arthritis
  • economics and quality improvement
  • economics and quality of life
  • economics and rheumatoid arthritis
  • economics and rheumatoid arthritis (RA)
  • economics and risk
  • Economics and systemic lupus erythematosus (SLE)
  • economics and tocilizumab
  • economics and treatment
  • ectonucleotidase
  • Edema
  • Education
  • education and educational research
  • education and epidemiologic methods
  • education and fibromyalgia
  • Education and gout
  • education and health disparities
  • Education and joint procedures
  • education and knowledge
  • Education and medical education
  • education and morbidity and mortality
  • education and musculoskeletal disorders
  • Education and online resources
  • education and professional development
  • education and race/ethnicity
  • education and rheumatic education
  • education and rheumatoid arthritis (RA)
  • education and social media
  • education and socioeconomic factors
  • education and technology
  • education and trainee
  • Education and ultrasonography
  • Education and ultrasound
  • education, medical
  • education, patient
  • educational innovation
  • educational innovation and clinical skills
  • educational innovation and educational research
  • educational innovation and evaluation
  • First |
  • « Previous Page
  • 14
  • 15
  • 16
  • 17
  • 18
  • [19]
  • 20
  • 21
  • 22
  • 23
  • 24
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology